Seattle-based biotech AltPep Corp. recently raised $44.4 million in equity funding as part of the company’s goal to raise $75 million for Alzheimer’s research.
AltPep aims to detect Alzheimer’s and Parkinson’s disease before symptoms appear by neutralizing early triggers known as “toxic soluble oligomers.”
“This funding will allow us to build upon our promising preliminary data demonstrating detection of Alzheimer’s disease at its earliest stages and further our preclinical therapeutic program,” said Valerie Daggett, AltPep CEO.